| Literature DB >> 34834074 |
Anca Becze1, Vanda Liliana Babalau Fuss1, Daniela Alexandra Scurtu1, Maria Tomoaia-Cotisel2, Aurora Mocanu2, Oana Cadar1.
Abstract
The content and composition of dietary supplements is of great interest due to their increasing consumption and variety of available brand offered in the market. Accurate determination of vitamins is important for the improvement of dietary supplement quality and nutrition assessments. In this regard, the simultaneous determination of vitamin D3 (calcitriol-CT and cholecalciferol-CHL) and K2 (menaquinone-4-MK-4 and menaquinone-7-MK-7) in dietary supplements was developed by using ultra-high-pressure liquid chromatography (UHPLC). The overall runtime per sample was above 35 min, with the retention times of 2.40, 6.59, 7.06, and 32.6 min for vitamin D3 (CT and CHL) and vitamin K2 (MK-4 and MK-7), respectively. The limits of detection and limits of quantification for the target nutritional compounds ranged between 0.04-0.05 µg/mL, respectively. The validation results indicated that the method had reasonable linearity (R2 ≥ 0.9990), good recovery (>82%), satisfactory intra-day precision (≤1.9%) and inter-day precision (≤3.5%), and high selectivity and specificity. The validated UHPLC method was demonstrated to be precise, accurate, and robust for the simultaneous determination of vitamins D3 (CT and CHL) and K2 (MK-4 and MK-7) in dietary supplements.Entities:
Keywords: UHPLC; calcitriol; cholecalciferol; menaquinone-4; menaquinone-7; method validation
Mesh:
Substances:
Year: 2021 PMID: 34834074 PMCID: PMC8624398 DOI: 10.3390/molecules26226982
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1HPLC chromatograms of the analyzed D3 and K2 vitamins: (a) calcitriol, CT; (b) cholecalciferol, CHL; (c) menaquinone-4, MK-4; (d) menaquinone-7, MK-7.
Chromatographic parameters.
| Parameter | CT | CHL | MK-4 | MK-7 |
|---|---|---|---|---|
| Retention time (min) | 2.38 | 6.59 | 7.07 | 32.5 |
| RSD of retention time (%) | 0.87 | 0.06 | 0.26 | 0.21 |
| Asymmetry factor | 1.31 | 1.25 | 1.21 | 1.11 |
| Resolution | 6.17 | 8.91 | 2.02 | - |
| Theoretical plates (N) | 10,600 | 10,846 | 11,484 | 13,141 |
Figure 2Calibration curves of: (a) calcitriol, CT, (b) cholecalciferol, CHL, (c) menaquinone, MK-4, and (d) menaquinone-7, MK-7.
Limit of detection (LOD) and limit of quantification (LOQ).
| No crt. | CT | CHL | MK-4 | MK-7 |
|---|---|---|---|---|
| 1 | 0.102 | 0.501 | 0.111 | 0.105 |
| 2 | 0.110 | 0.511 | 0.113 | 0.103 |
| 3 | 0.108 | 0.508 | 0.114 | 0.111 |
| 4 | 0.109 | 0.507 | 0.102 | 0.102 |
| 5 | 0.108 | 0.516 | 0.110 | 0.111 |
| 6 | 0.101 | 0.507 | 0.109 | 0.114 |
| Average | 0.106 | 0.508 | 0.110 | 0.108 |
| SD | 0.0038 | 0.0050 | 0.0043 | 0.0050 |
| %RSD | 3.60 | 0.98 | 3.88 | 4.61 |
| n | 6 | 6 | 6 | 6 |
| LOD (µg/mL) | 0.011 | 0.015 | 0.013 | 0.015 |
| LOQ (µg/mL) | 0.038 | 0.050 | 0.043 | 0.050 |
Repeatability and recovery for the limit of quantification (LOQ).
| No crt. | CT | CHL | MK-4 | MK-7 |
|---|---|---|---|---|
| 1 | 0.05 | 0.06 | 0.04 | 0.07 |
| 2 | 0.05 | 0.07 | 0.04 | 0.04 |
| 3 | 0.05 | 0.05 | 0.03 | 0.06 |
| 4 | 0.05 | 0.05 | 0.04 | 0.06 |
| 5 | 0.04 | 0.07 | 0.05 | 0.05 |
| 6 | 0.05 | 0.04 | 0.05 | 0.06 |
| SD | 0.01 | 0.01 | 0.01 | 0.01 |
| %RSD | 13.1 | 17.8 | 15.3 | 16.8 |
| Average (µg/mL) | 0.05 | 0.06 | 0.04 | 0.06 |
| Recovery (%) | 115 | 111 | 104 | 112 |
Method recovery.
| Analyte | n | Fortified (µg/g) | Recovered (µg/g) | Recovered Mean (µg/g) | SD | RSD | Recovery |
|---|---|---|---|---|---|---|---|
| CT | 3 | 12.5 | 10.5 | 10.6 | 0.28 | 2.60 | 85 |
| 10.9 | |||||||
| 10.4 | |||||||
| CHL | 3 | 12.6 | 10.4 | 10.3 | 0.35 | 3.37 | 81 |
| 10.5 | |||||||
| 9.87 | |||||||
| MK-4 | 3 | 6.12 | 5.07 | 5.08 | 0.10 | 1.88 | 83 |
| 5.18 | |||||||
| 4.99 | |||||||
| MK-7 | 3 | 6.08 | 4.97 | 4.97 | 0.11 | 2.11 | 82 |
| 4.86 | |||||||
| 5.07 |
Method precision.
| Sample | CT | CHL | MK-4 | MK-7 |
|---|---|---|---|---|
| S1 | 40.12 | 40.56 | 30.24 | 30.25 |
| S2 | 41.03 | 39.02 | 30.25 | 31.06 |
| S3 | 39.89 | 40.15 | 30.78 | 31.07 |
| S4 | 40.12 | 40.23 | 29.97 | 30.48 |
| S5 | 40.18 | 40.99 | 29.44 | 29.67 |
| S6 | 41.07 | 41.08 | 30.74 | 30.47 |
| Average | 40.40 | 40.34 | 30.24 | 30.50 |
| SD | 0.51 | 0.75 | 0.50 | 0.53 |
| %RSD | 1.27 | 1.86 | 1.66 | 1.73 |
Method reproducibility.
| Sample | No crt. | CT | CHL | MK-4 | MK-7 |
|---|---|---|---|---|---|
| Lot 1 | Day 1 | 10.0 | 10.2 | 5.31 | 5.22 |
| Day 2 | 10.7 | 10.4 | 5.20 | 5.13 | |
| Day 3 | 10.2 | 10.6 | 4.94 | 4.91 | |
| Day 4 | 10.5 | 10.2 | 5.31 | 5.31 | |
| Day 5 | 10.3 | 10.0 | 5.17 | 5.39 | |
| Average | 10.4 | 10.3 | 5.19 | 5.20 | |
| SD | 0.26 | 0.24 | 0.15 | 0.18 | |
| %RSD | 2.53 | 2.33 | 2.93 | 3.57 | |
| Lot 2 | Day 1 | 12.5 | 12.8 | 6.19 | 6.23 |
| Day 2 | 12.3 | 13.0 | 6.32 | 6.12 | |
| Day 3 | 12.3 | 12.0 | 6.52 | 6.31 | |
| Day 4 | 11.9 | 12.5 | 6.35 | 6.54 | |
| Day 5 | 12.5 | 12.4 | 6.16 | 6.65 | |
| Average | 12.3 | 12.5 | 6.31 | 6.37 | |
| SD | 0.24 | 0.36 | 0.14 | 0.22 | |
| %RSD | 1.98 | 2.88 | 2.31 | 3.41 | |
| Lot 3 | Day 1 | 30.2 | 29.2 | 10.3 | 10.6 |
| Day 2 | 30.5 | 30.7 | 10.9 | 10.4 | |
| Day 3 | 31.0 | 31.5 | 10.2 | 10.9 | |
| Day 4 | 30.9 | 30.9 | 10.2 | 10.3 | |
| Day 5 | 30.1 | 31.0 | 10.3 | 9.94 | |
| Average | 30.5 | 30.6 | 10.4 | 10.4 | |
| SD | 0.40 | 0.89 | 0.27 | 0.34 | |
| %RSD | 1.31 | 2.90 | 2.62 | 3.25 |
Method robustness.
| Analyte | Chromatographic | Column | Flow Rate | Mobile Phase Ratio (%) | Wavelength | ||||
|---|---|---|---|---|---|---|---|---|---|
| 25 | 35 | 0.9 | 1.1 | 96 | 100 | 262 | 268 | ||
| CT | Assay (%) | 100 | 100 | 100 | 101 | 100 | 100 | 99 | 100 |
| Retention time (min) | 2.46 | 2.14 | 2.42 | 2.27 | 2.45 | 2.14 | 2.40 | 2.40 | |
| Asymmetry factor | 1.41 | 1.39 | 1.40 | 1.32 | 1.41 | 1.29 | 1.30 | 1.31 | |
| Resolution | 5.23 | 5.98 | 5.12 | 6.08 | 4.98 | 5.66 | 6.02 | 6.15 | |
| CHL | Assay (%) | 101 | 101 | 101 | 100 | 100 | 100 | 100 | 100 |
| Retention time (min) | 6.84 | 6.46 | 6.68 | 6.48 | 6.90 | 6.32 | 6.59 | 6.58 | |
| Asymmetry factor | 1.54 | 1.28 | 1.53 | 1.31 | 1.61 | 1.24 | 1.26 | 1.25 | |
| Resolution | 7.65 | 8.02 | 7.16 | 8.99 | 7.68 | 8.64 | 8.89 | 8.87 | |
| MK-4 | Assay (%) | 100 | 100 | 100 | 100 | 100 | 101 | 101 | 100 |
| Retention time (min) | 7.24 | 6.88 | 7.27 | 6.98 | 7.29 | 6.89 | 7.09 | 7.10 | |
| Asymmetry factor | 1.56 | 1.20 | 1.58 | 1.22 | 1.98 | 1.22 | 1.20 | 1.21 | |
| Resolution | 1.98 | 2.03 | 1.97 | 2.01 | 1.96 | 2.03 | 2.00 | 2.01 | |
| MK-7 | Assay (%) | 100 | 101 | 101 | 101 | 100 | 100 | 100 | 100 |
| Retention time (min) | 32.7 | 32.4 | 32.8 | 32.5 | 32.8 | 32.3 | 32.5 | 32.5 | |
| Asymmetry factor | 1.34 | 1.09 | 1.42 | 1.11 | 1.39 | 1.09 | 1.10 | 1.10 | |
| Resolution | 100 | 100 | 100 | 101 | 100 | 100 | 100 | 100 | |
Assay results of vitamins D3 and K2 by HPLC in commercial dietary supplements.
| Analyte | Sample | Concentration Found ± SD | %RSD | Recovery |
|---|---|---|---|---|
|
| SD-CT1 | 0.256 ± 0.01 | 4.42 | 102 |
| SD-CT2 | 0.517 ± 0.01 | 2.05 | 103 | |
|
| DS-CHL@MK4 | 25.7 ± 0.57 | 2.20 | 103 |
| DS-CHL@MK7 | 6.21 ± 0.23 | 3.76 | 96 | |
| DS-CHL | 25.6 ± 0.35 | 1.38 | 103 | |
| DS-CHL@MK7 | 125 ± 1.84 | 1.47 | 100 | |
|
| DS-CHL@MK4 | 100 ± 1.54 | 1.54 | 100 |
| DS-MK4 | 52 ± 0.85 | 1.62 | 105 | |
|
| DS-CHL@MK7A | 51 ± 0.97 | 1.90 | 102 |
| DS-MK4@MK7 | 52 ± 0.63 | 1.21 | 104 | |
| DS-CHL@MK7B | 104 ± 1.80 | 1.74 | 104 |
Figure 3Chromatogram plot of dietary supplement DS-CHL@MK4.
Dietary supplements and synthetic drugs analyzed (capsule form).
| Sample | Concentration of Vitamins (µg/Capsule) | |||
|---|---|---|---|---|
| CT | CHL | MK-4 | MK-7 | |
| DS-CHL@MK4 | - | 25 | 100 | - |
| DS-MK4 | - | - | 100 | - |
| DS-CHL@MK7A | - | 6.25 | - | 50 |
| DS-CHL | - | 25 | - | - |
| DS-MK4@MK7 | - | - | 50 | 50 |
| DS-CHL@MK7B | - | 125 | - | 100 |
| SD-CT1 | 0.25 | - | - | - |
| SD-CT2 | 0.5 | - | - | - |